Last Updated: November 16, 2026

sotagliflozin - Profile

« Back to Dashboard


What are the generic sources for sotagliflozin and what is the scope of freedom to operate?

Sotagliflozin is the generic ingredient in one branded drug marketed by Lexicon Pharms Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for sotagliflozin
International Patents:81
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for sotagliflozin
Generic Entry Date for sotagliflozin*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for sotagliflozin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No 8,476,413 ⤷  Start Trial Y Y ⤷  Start Trial
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No 7,781,577 ⤷  Start Trial Y Y ⤷  Start Trial
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No 8,217,156 ⤷  Start Trial Y Y ⤷  Start Trial
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-002 May 26, 2023 RX Yes Yes 8,476,413 ⤷  Start Trial Y Y ⤷  Start Trial
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-002 May 26, 2023 RX Yes Yes 7,781,577 ⤷  Start Trial Y Y ⤷  Start Trial
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-002 May 26, 2023 RX Yes Yes 8,217,156 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for sotagliflozin

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Guidehouse Germany GmbH Zynquista sotagliflozin EMEA/H/C/004889Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy., Withdrawn no no no 2019-04-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for sotagliflozin

Country Patent Number Title Estimated Expiration
Argentina 063047 ⤷  Start Trial
Austria E496888 ⤷  Start Trial
Australia 2007304971 ⤷  Start Trial
Brazil PI0717156 ⤷  Start Trial
Canada 2664688 ⤷  Start Trial
China 101343296 ⤷  Start Trial
China 103254119 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for sotagliflozin

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2089361 19C1053 France ⤷  Start Trial PRODUCT NAME: SOTAGLIFLOZINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1363 20190430
2089361 122019000077 Germany ⤷  Start Trial PRODUCT NAME: SOTAGLIFLOZIN, ODER EIN PHARMAZEUTISCH ZULAESSIGES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1363 20190426
2089361 2019/044 Ireland ⤷  Start Trial PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/19/1363 20190430
2089361 1990043-0 Sweden ⤷  Start Trial PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1363 20190430
2089361 CA 2019 00042 Denmark ⤷  Start Trial PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430
2089361 132019000000113 Italy ⤷  Start Trial PRODUCT NAME: SOTAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZYNQUISTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1363, 20190430
2089361 SPC/GB19/054 United Kingdom ⤷  Start Trial PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/19/1363 (NI) 20190430; UK PLGB 53567/0001 20190430
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Last updated: February 3, 2026

tagliflozin: Investment Scenario, Market Dynamics, and Financial Trajectory

Summary
Sotagliflozin is an investigational dual SGLT1 and SGLT2 inhibitor developed primarily for managing Type 1 and Type 2 diabetes mellitus. While initial regulatory pursuits have faced hurdles, the evolving landscape of diabetes treatment, combined with increasing global prevalence, presents potential opportunities. This analysis explores the current investment prospects, market dynamics, and projected financial trajectory of sotagliflozin, providing critical insights for stakeholders.


What is the Status of Sotagliflozin Development and Regulatory Approvals?

Key Aspect Details
Developer Lexicon Pharmaceuticals (acquired by Sanofi in 2018), and involved companies such asLexicon and Sanofi
Regulatory Status Previously submitted NDA/BLA to FDA (2019), EMA approval sought; approvals denied or delayed in some territories
Major Milestones FDA declined approval for Type 1 diabetes in 2021 citing insufficient efficacy and safety concerns (e.g., DKA risk)
Current Status Ongoing Phase 3 trials in Type 2 diabetes; no recent approval approvals in major markets

Implication: Significant regulatory setbacks have limited commercialization, impacting immediate revenue potential but maintaining long-term development prospects in robust markets.


Market Dynamics Influencing Sotagliflozin Investment

Market Drivers Impact
Rising Global Diabetes Prevalence Estimated to reach 700 million by 2045 (IDF, 2021)
Growing Adoption of SGLT Inhibitors SGLT2 inhibitors like empagliflozin and canagliflozin have gained FDA approval, signaling market acceptance
Unmet Needs in Type 1 Diabetes Current lack of approved adjunct therapies, though safety concerns, limits immediate opportunities
Cardiovascular and Kidney Benefits Demonstrated by other SGLT2 inhibitors, these benefits position new entrants favorably
Regulatory Environment Stringent safety requirements, particularly for Type 1 diabetes, could constrain market entry

Market Challenges

  • Safety concerns such as diabetic ketoacidosis (DKA) have hindered approvals, notably in Type 1 diabetes.
  • Competition from established SGLT2 inhibitors like Jardiance (empagliflozin), Invokana (canagliflozin), and Farxiga (dapagliflozin).
  • Patent expirations of competitor drugs could influence pricing and market share.

Market Opportunities

  • Expansion of indications: Cardiovascular and chronic kidney disease (CKD) subsets |
  • Differentiation via dual SGLT1/SGLT2 inhibition capabilities |
  • Growing preference for oral, once-daily diabetes therapies |

Financial Trajectory and Investment Outlook for Sotagliflozin

Phase Estimated Timelines Revenue Prospects Risks
Development Ongoing Phase 3 trials for T2D; potential filings in next 1-2 years Moderate to high depending on success Trial failures, safety issues
Regulatory Approval 2024–2026 (if successful) Market launch potentially in 2025–2027 Denial or delay similar to past experience
Market Penetration Potential peak in 2028–2030 Revenue estimates vary: – Early adoption limited by safety concerns – Market share influenced by competitors – Pricing pressures from generics

Financial Forecasts (Hypothetical):

Year Revenue Estimate Key Assumptions
2024 $0 (pre-approval) Continued trials, no commercialization
2025 $50–100 million First launches in select markets, limited indications
2027 $300–500 million Broadened indications, expanded payer coverage
2030 $1 billion+ Market maturation, potential global reach

Note: These projections depend on successful regulatory approvals, market acceptance, and safety profile management.


Comparison With Competitors

Comparator Indication Market Status Annual Sales (2022) Key Differentiators Regulatory Challenges
Empagliflozin (Jardiance) T2D, CV risk reduction Approved globally $10.6B Proven CV benefit Established safety profile
Canagliflozin (Invokana) T2D, CKD Approved $2.4B Strong brand presence Safety concerns (amputation risk)
Dapagliflozin (Farxiga) T2D, HF, CKD Approved $4.2B Versatile indications Similar safety issues
Sotagliflozin T1D (pending), T2D Under development N/A Dual SGLT1/SGLT2 action Past safety hurdles

Observation: Entry barriers include safety profile concerns and established market dominance by incumbents.


Deep Dive into Investment Risks and Rewards

Risks:

  • Regulatory failures akin to previous denials or restrictions for Type 1 diabetes indications.
  • Safety profile controversies, especially DKA risk.
  • Market saturation with existing SGLT2 inhibitors.
  • Patent cliffs of competitors, leading to pricing pressures.
  • Delayed development timelines impacting ROI.

Rewards:

  • Potential first-in-class dual SGLT1/SGLT2 inhibitor.
  • Access to high-growth diabetes and CKD markets.
  • Expansion opportunities into new indications like obesity or heart failure.
  • Strategic partnerships or licensing deals for global commercialization.

Regulatory Policies and Patent Landscape

Policy Element Implication for Sotagliflozin
FDA & EMA Guidelines Emphasize safety, particularly in T1D
Data Requirements Larger safety datasets needed, raising R&D costs
Patent Life Estimated until 2030s, with opportunities for exclusivity extensions
Patent Cliffs Impacted by generics for other SGLT2 inhibitors

FAQs

  1. What are the primary challenges facing sotagliflozin's commercialization?
    Regulatory hurdles, safety concerns (notably DKA), and stiff competition from established SGLT2 inhibitors limit immediate market opportunities.

  2. Can sotagliflozin succeed in the diabetic market despite previous setbacks?
    Yes, if safety profiles are improved or sufficiently demonstrated, and if regulatory agencies are convinced of its benefits over risks.

  3. What differentiates sotagliflozin from other SGLT inhibitors?
    Its dual mechanism targeting both SGLT1 and SGLT2, which could offer additional glycemic benefits or gastrointestinal effects, depending on clinical outcomes.

  4. How will market dynamics evolve for dual SGLT1/SGLT2 inhibitors?
    Growth depends on efficacy, safety, and label breadth; regulatory acceptance in T1D remains uncertain.

  5. Is investing in sotagliflozin a high-risk or high-reward opportunity?
    It is a high-risk, high-reward scenario; promising if regulatory and safety hurdles are overcome, offering substantial upside in a large and expanding market.


Key Takeaways

  • Development Status & Regulation: Sotagliflozin remains in late-stage development, with regulatory approval hurdles chiefly due to safety concerns, particularly in T1D. Successful approval hinges on demonstrating an improved safety profile and clear benefits over existing treatments.

  • Market Outlook: The global diabetes market is expanding rapidly, with a significant shift towards oral SGLT2 inhibitors. Dual SGLT1/SGLT2 inhibitors like sotagliflozin could carve niche indications if safety issues are mitigated.

  • Financial Projection: While immediate revenues are limited, a potential launch around 2025–2027 could generate hundreds of millions in revenue, scaling to over a billion dollars if approved for multiple indications across major markets.

  • Investment Risks & Opportunities: Regulatory setbacks and safety concerns are major risks, but successful development could secure a competitive position in the growing diabetic and CKD markets. Strategic partnerships are essential for global commercialization.

  • Strategic Recommendations: Investors should monitor ongoing trial results, regulatory communications, and competitor developments. Diversification across the SGLT landscape and cautious capital deployment are advised until clarity on safety and efficacy emerges.


References

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.
[2] FDA. (2021). FDA Briefing Document, Sotagliflozin NDA review.
[3] Sanofi. (2022). Annual Report and Regulatory Filings.
[4] MarketsandMarkets. (2022). Global SGLT Inhibitors Market Report.
[5] European Medicines Agency. (2022). Product Data and Review Processes.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.